2023-06-28 16:32:00 ET
- VistaGen Therapeutics press release ( NASDAQ: VTGN ): FY GAAP EPS of -$8.51 misses by $0.11 .
- At March 31, 2023, the Company had cash and cash equivalents of approximately $16.6 million.
- As of June 27, 2023, the Company had 7,872,479 shares of common stock outstanding, which reflects the impact of the recent 1-for-30 reverse stock split, which enabled the Company to regain full compliance with the continued listing standards of the Nasdaq Capital Market.
For further details see:
VistaGen Therapeutics GAAP EPS of -$8.51 misses by $0.11